Dyne Therapeutics to Present at November Investor Conferences
07 Novembro 2023 - 9:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced that management is scheduled to present at the
following investor conferences in November:
- Stifel 2023 Healthcare Conference, fireside
chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York
- Piper Sandler 35th Annual Healthcare
Conference, fireside chat on Tuesday, November 28, 2023 at
1:30 p.m. ET in New York
A live webcast of each presentation will be
available in the Investors & Media section of Dyne’s website at
https://investors.dyne-tx.com/news-and-events/events-and-presentations
and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases.
With its proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD). For more information, please visit
https://www.dyne-tx.com/, and follow us on X, LinkedIn and
Facebook.
Contact:
Dyne TherapeuticsAmy Reillyareilly@dyne-tx.com
857-341-1203
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024